Polyrizon partners with Clearmind to develop intranasal MEAI formulation
Go back to Polyrizon partners with Clearmind to develop intranasal MEAI formulation| (NASDAQ: CMND) | Delayed: 1.46 -0.16 (9.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.62 | 52 Week High | $ | |||
| Open | $1.56 | 52 Week Low | $ | |||
| Day High | $1.56 | P/E | N/A | |||
| Day Low | $1.43 | EPS | $ | |||
| Volume | 329,192 | |||||
| (NASDAQ: PLRZ) | Delayed: 11.26 -2.78 (19.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.04 | 52 Week High | $ | |||
| Open | $13.85 | 52 Week Low | $ | |||
| Day High | $13.88 | P/E | N/A | |||
| Day Low | $10.31 | EPS | $ | |||
| Volume | 88,419 | |||||

